Peripheral Perfusion and Tissue Oxygenation Improvement Induced by Antihypertensive Medication Combined with Lipoidoproteinosis Treatment

  • G. Cicco
  • P. Vicenti
  • A. Pirrelli
  • A. J. van der Kleij
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 411)


The presence of microcirculatory disorders (i.e. increase in blood viscosity) as well as increased aggregation rate of erythrocytes has been described (1,2) in non-treated hypertensive patients. The increased aggregation rate has been linked to microvasculopathy and hyperfibrinogenemia frequently present in treated hypertensive patients with metabolic disturbances (such as diabetes, lipoidoproteinosis) (3,4,5). Lipoidoproteinosis, haemorheological and clotting disorders are often the underlying base for serious pathology (ictus, myocardial infarction, etc.) complicating hypertension (6). It is noted that hypertension itself not only represents an independent atherogenic risk factor, but also low “shear stress” within the vessel wall and in addition the level of systolic-diastolic oscillation favours the formation of atherosclerotic patches. All these events are notably increased in the presence of other risk factors for cardiovascular pathology such as smoking, diabetes, blood hyperviscosity and lipoidoproteinosis (7). Furthermore, microcirculatory disorders in hypertensive patients are often associated with a reduction in peripheral oxygen delivery (8). Reduction of blood pressure values and metabolic disturbances in hypertensive patients may improve peripheral perfusion and cellular oxygen delivery.


Hypertensive Patient Peripheral Arterial Occlusive Disease Peripheral Perfusion Uncertain Objectivity Lipid Pattern 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harris I., Loughlin G., The viscosity of blood in high blood pressure. Am. J.Med. 1980, 23:451–464.Google Scholar
  2. 2.
    Lorient-Roudat M.F., Roudat R., Freyburger G.L. Hemorheological abnormalities in essential hypertension. Clin. Hemorheol. 1987, 7:537.Google Scholar
  3. 3.
    Petraliot A., Malatino L.S., Fione C.F. Erythrocyte aggregation in different stages of arterial hypertension. Tromb. Haemost. 1985, 54:555.Google Scholar
  4. 4.
    Tsinahdzvbishvili B., Beritashvili N., Mcheolishvili G., Erythrocyte aggregability in essential hypertension. Abstract book, Proc. 1. ICCH/8 ECCH Vienna 1993, 13 — 3:401.Google Scholar
  5. 5.
    Cicco G., Dolce E., Mancini M., Pirrelli A., Atherosclerosis and hemorheology in hypertension; Organ damage. Medit. J. Surg. Med. 1994, 3: 131–138.Google Scholar
  6. 6.
    McGill M.C., Adria S. Stella J., Corbonell L.M. General Undings of international atherosclerosis. Project Lab. Inv. 1968, 18:498.Google Scholar
  7. 7.
    Kannel W.B., Wolf P.A., McGee D.L. Systolic blood pressure arterial, rigidity and risk of stroke. The Framingham study. J. Am. Med. 1981, 245: 1225.Google Scholar
  8. 8.
    Cesarone M.R., Laurora G., Belcardo G.U., Microcirculation in systemic hypertension. Angiology. 1992, 43(11): 899–903.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • G. Cicco
    • 1
  • P. Vicenti
    • 1
  • A. Pirrelli
    • 1
  • A. J. van der Kleij
    • 2
  1. 1.Department of Internal Medicine and Oncology, Hypertension CenterUniversity of BariItaly
  2. 2.Department of SurgeryAcademic Medical Center/University of AmsterdamAmsterdamThe Netherlands

Personalised recommendations